<SEC-DOCUMENT>0001598599-26-000008.txt : 20260721
<SEC-HEADER>0001598599-26-000008.hdr.sgml : 20260721
<ACCEPTANCE-DATETIME>20260721060556
ACCESSION NUMBER:		0001598599-26-000008
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260721
FILED AS OF DATE:		20260721
DATE AS OF CHANGE:		20260721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	9695002Y8420ZB8HJE29

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		261188102

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a2607216kincorporatediph1.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ifc56ec5cd2b740dba127e4cbb1be9344_1"></div><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.55pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="margin-top:0.1pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-top:0.1pt;padding-left:199.2pt;padding-right:199.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:218%">Washington, D.C. 20549 FORM 6-K</font></div><div style="margin-top:0.5pt;padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Date of report&#58; July 21, 2026</font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Commission File Number&#58; 001-39084</font></div><div style="margin-top:0.05pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.45pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Translation of registrant's name into English)</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.4pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">117 Avenue de Luminy&#8212;BP 30191</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">13009 Marseille, France</font></div><div style="margin-top:0.45pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">+ 33 (0) 4 30 30 30</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Address of principal executive office)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:56.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:240%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F &#91; X &#93;&#160;&#160;&#160;&#160;Form 40-F &#91; &#93;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION BY REFERENCE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quotation from Jonathan Dickinson, Chief Executive Officer at Innate Pharma, the reference to the live webcast, and the related Internet and telephone links) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333-282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.</font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.45pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT INDEX</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Description</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:31.9pt;text-indent:-38.25pt"><font><br></font></div><div style="padding-left:31.9pt;text-indent:-38.25pt"><font style="color:#0066cc;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%">99.1&#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a260721exhibit991.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Press Release dated July 21, 2026</a></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ifc56ec5cd2b740dba127e4cbb1be9344_4"></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.55pt;padding-right:14.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:280.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%">INNATE PHARMA S.A.</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:280.1pt;padding-right:5.8pt;text-indent:-274.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:125%">Date&#58; July 21, 2026&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; JONATHAN DICKINSON&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:125%"> Name&#58;&#160;&#160;&#160;&#160;Jonathan Dickinson</font></div><div style="padding-left:333.15pt;text-indent:-53.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:9.05pt">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-top:0.45pt;padding-left:247.85pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a260721exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id7276e1ac02c44b69b2dcba421326ccd_1"></div><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-right:5.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT 99.1</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-right:-24.72pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INNATE PHARMA ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 1 DOSE ESCALATION STUDY OF IPH4502, A NOVEL NECTIN-4 EXATECAN ANTIBODY-DRUG CONJUGATE (ADC) </font></div><div style="margin-top:0.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Marseille, France, July 21, 2026, 7&#58;00 AM CEST</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #808080;padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:12pt;padding-left:22.77pt;padding-right:2.77pt;text-align:justify;text-indent:-20pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.15pt">Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:22.77pt;padding-right:2.77pt;text-align:justify;text-indent:-20pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.15pt">Favorable safety profile observed to date, with limited hematological toxicity </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:22.77pt;padding-right:2.77pt;text-align:justify;text-indent:-20pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:16.15pt">Objective responses observed in heavily pre-treated patients with post-EV UC, as well as NSCLC and HNSCC, supporting the potential of IPH4502 in populations with high unmet medical need</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#808080;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Marseille, France, July 21, 2026, 7&#58;00 AM CEST</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma SA (Euronext Paris&#58; IPH&#59; Nasdaq&#58; IPHA) (&#34;Innate&#34; or the &#34;Company&#34;), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and will include data from 76 patients, guiding Phase 1 dose optimization in selected tumor types.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPH4502-101 Phase 1 study is an open-label, multi-center study evaluating the safety, tolerability, and preliminary anti-tumor activity of IPH4502 as a single agent in patients with advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast, ovarian, gastric, esophageal, and colorectal cancers. The Phase 1 dose-escalation part has recruited 76 patients in France and the United States.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, IPH4502 continues to show a favorable safety profile, with limited hematological toxicity, supporting the hypothesis that the Company&#8217;s proprietary linker leads to a slow release of free exatecan, minimizing toxicity. Preliminary anti-tumor activity continues to be observed in heavily pre-treated patients with advanced solid tumors, with objective responses reported in UC post enfortumab vedotin, as well as in NSCLC and HNSCC. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completing enrollment in the dose escalation marks an important milestone for IPH4502. The data generated to date continue to support the differentiated design of IPH4502, notably through the limited hematological toxicity observed to date, which we believe might reflect the benefits of our proprietary linker. We look forward to the dose escalation dataset by year-end, which will guide our path into dose optimization and further define the clinical potential of IPH4502</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; said Sonia Quaratino,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EVP Chief Medical Officer of Innate Pharma.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#808080;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About IPH4502</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPH4502 is Innate Pharma's proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance, and without the need for CYP2D6 genotyping. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). In preclinical studies, IPH4502 demonstrated anti-tumor activity in EV-resistant tumor models and in tumors with low and heterogeneous </font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nectin-4 expression, supporting its potential applicability across solid tumor types beyond urothelial carcinoma (UC). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#808080;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Innate Pharma</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next generation antibody therapeutics. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma is advancing a portfolio of differentiated potential first- and&#47;or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer (NSCLC).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn</font><font style="color:#0000ff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and X.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#808080;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Information about Innate Pharma shares</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ISIN code</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ticker code</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEI</font></div></td><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FR0010331421</font></div><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Euronext&#58; IPH Nasdaq&#58; IPHA</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9695002Y8420ZB8HJE29</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#808080;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclaimer on forward-looking information and risk factors</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks and uncertainties, please refer to the Risk Factors (&#8220;Facteurs de Risque&#34;) section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http&#58;&#47;&#47;www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company&#8217;s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:1.5pt 1.02pt 1.5pt 1pt;text-align:justify;vertical-align:top"><font style="color:#808080;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:100%">For more information</font></td></tr><tr><td colspan="3" style="padding:1.5pt 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Investors &#38; Media Relations</font></div><div style="margin-top:2.65pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innate Pharma&#160;</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">St&#233;phanie Cornen&#160;</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stephanie.cornen&#64;innate-pharma.fr&#160;</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Relations&#160;</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investors&#64;innate-pharma.fr&#160;</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Media&#160;</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">communication&#64;innate-pharma.fr</font><font style="color:#0000ff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:49.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
